

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of 37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A1		502,504	08-01-1893	Thoms	
A2		1,792,156	02-10-1931	Fitzky	
A3		2,046,375	07-07-1936	Goldstein et al.	
A4		2,093,265	09-14-1937	Coffey et al.	
A5		2,288,422	06-30-1942	Rohm	
A6		2,649,476	08-18-1953	Martin	
A7		2,683,082	07-06-1954	Hill et al.	
A8		2,722,544	11-01-1955	Martin	
A9		2,745,874	05-15-1956	Schetty et al.	
A10		2,781,330	02-12-1957	Downey	
A11		2,797,214	06-25-1957	Bossard	
A12		2,867,659	01-06-1959	Model et al.	
A13		2,877,268	03-10-1959	Applegath et al.	
A14		2,960,488	11-15-1960	Tamblyn et al.	
A15		2,973,386	02-28-1961	Weldon	
A16		3,151,023	09-29-1964	Martin	
A17		3,200,035	08-10-1965	Martin et al.	
A18		3,230,141	01-18-1966	Frick et al.	
A19		3,284,433	11-08-1966	Becker et al.	
A20		3,424,760	01-28-1969	Helsley et al.	
A21		3,424,761	01-28-1969	Helsley et al.	
A22		3,424,762	01-28-1969	Helsley	
A23		3,547,940	12-15-1970	Brantley	
A24		3,639,668	02-01-1972	Alles et al.	
A25		3,646,059	02-29-1972	Brantley	
A26		3,668,222	06-06-1972	Hauser	
A27		3,689,550	09-05-1972	Schellenbaum et al.	
A28		3,743,498	07-03-1973	Brantley	
A29		3,754,887	08-28-1973	Brantley	
A30		3,823,161	07-09-1974	Lesser	
A31		3,828,001	08-06-1974	Broad et al.	
A32		3,860,645	01-14-1975	Nikawitz	
A33		3,990,879	11-09-1976	Soper	
A34		4,001,256	01-04-1977	Callahan et al.	
A35		4,009,847	03-01-1977	Aldrich et al.	
A36		4,042,372	08-16-1977	Harper	
A37		4,062,861	12-13-1977	Yukinaga et al.	
A37a		4,063,928	12-20-1977	Johnston	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A38		4,071,524	01-31-1978	Banitt	
A39		4,103,022	07-25-1978	Sirrenberg et al.	
A40		4,111,680	09-05-1978	Yukinaga et al.	
A41		4,111,683	09-05-1978	Singer	
A42		4,116,671	09-26-1978	Yukinaga et al.	
A43		4,173,637	11-06-1979	Nishiyama et al.	
A44		4,173,638	11-06-1979	Nishiyama et al.	
A45		4,183,854	01-15-1980	Crossley	
A46		4,212,981	07-15-1980	Yukinaga et al.	
A47		4,240,820	12-23-1980	Dickore et al.	
A48		4,279,639	07-21-1981	Okamoto et al.	
A48a		4,293,328	10-06-1981	Yukinaga et al.	
A49		4,358,596	11-09-1982	Krüger	
A50		4,405,644	09-20-1983	Kabbe et al.	
A51		4,410,697	10-18-1983	Török et al.	
A52		4,437,878	03-20-1984	Acker et al.	
A53		4,458,380	08-28-1984	O'Doherty et al.	
A54		4,473,579	09-25-1984	Devries et al.	
A55		4,499,097	02-12-1985	Tomcufcik et al.	
A56		4,511,571	04-16-1985	Böger et al.	
A57		4,514,571	04-30-1985	Nakai et al.	
A58		4,526,997	07-02-1985	O'Doherty et al.	
A59		4,540,566	09-10-1985	Davis et al.	
A60		4,546,191	10-08-1985	Nishiyama et al.	
A61		4,587,240	05-06-1986	Hider et al.	
A62		4,623,662	11-18-1986	DeVries	
A63		4,643,849	02-17-1987	Hirai et al.	
A64		4,740,520	04-26-1988	Hallenbach et al.	
A65		4,760,063	07-26-1988	Hallenbach et al.	
A66		4,775,763	10-04-1988	Dalton et al.	
A67		4,808,588	02-28-1989	King	
A68		4,820,871	04-11-1989	Kissener et al.	
A69		4,863,924	09-05-1989	Haga et al.	
A69a		4,921,525	05-01-1990	Grossman et al.	
A70		4,973,675	11-27-1990	Israel et al.	
A70a		4,977,169	12-11-1990	Häusermann et al.	
A71		4,983,605	01-08-1991	Kondo et al.	
A72		4,985,449	01-15-1991	Haga et al.	
A72a		4,996,325	02-26-1991	Kristinsson	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A73		5,036,072	07-30-1991	Nakajima et al.	
A74		5,059,614	10-22-1991	Lepage et al.	
A75		5,063,247	11-05-1991	Sekiya et al.	
A76		5,098,907	03-24-1992	Kondo et al.	
A77		5,100,883	03-31-1992	Schiehser	
A78		5,118,677	06-02-1992	Caufield	
A79		5,118,678	06-02-1992	Kao et al.	
A80		5,120,842	06-09-1992	Failli et al.	
A81		5,130,331	07-14-1992	Pascual	
A82		5,151,344	09-29-1992	Abe et al.	
A83		5,151,413	09-29-1992	Caulfield et al.	
A84		5,182,360	11-10-1992	Creswell et al.	
A84a		5,177,110	01-05-1993	Oechslein et al.	
A85		5,185,358	02-09-1993	Creswell et al.	
A86		5,256,790	10-26-1993	Nelson	
A87		5,258,389	11-02-1993	Goulet et al.	
A88		5,270,458	12-14-1993	Lemischka	
A89		5,283,354	02-01-1994	Lemischka	
A90		5,312,820	05-17-1994	Ashton et al.	
A91		5,319,099	06-07-1994	Kamata et al.	
A92		5,378,725	01-03-1995	Bonjouklian et al.	
A93		5,399,566	03-21-1995	Katano et al.	
A94		5,423,905	06-13-1995	Fringeli	
A95		5,429,918	07-04-1995	Seto et al.	
A96		5,432,468	07-11-1995	Moriyama et al.	
A97		5,441,947	08-15-1995	Dodge et al.	
A98		5,447,957	09-05-1995	Adams et al.	
A99		5,456,920	10-10-1995	Matoba et al.	
A100		5,468,773	11-21-1995	Dodge et al.	
A101		5,470,882	11-28-1995	Dixon et al.	
A102		5,480,906	01-02-1996	Creemer et al.	
A103		5,500,424	03-19-1996	Nagamine et al.	
A104		5,508,288	04-16-1996	Forbes et al.	
A105		5,547,966	08-20-1996	Atwal et al.	
A106		5,559,137	09-24-1996	Adams et al.	
A107		5,596,001	01-21-1997	Hamanaka	
A108		5,597,719	01-28-1997	Freed et al.	
A109		5,624,937	04-29-1997	Reel et al.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A110		5,656,612	08-12-1997	Monia	
A111		5,658,903	08-19-1997	Adams et al.	
A111a		5,667,226	09-16-1997	Janich	
A112		5,696,138	12-09-1997	Olesen et al.	
A113		5,698,581	12-16-1997	Kleemann et al.	
A114		5,710,094	01-20-1998	Minami et al.	
A115		5,721,237	02-24-1998	Myers et al.	
A116		5,726,167	03-10-1998	Dodge et al.	
A117		5,747,498	05-05-1998	Schnur et al.	
A118		5,773,459	06-30-1998	Tang et al.	
A119		5,777,097	07-07-1998	Lee et al.	
A120		5,780,262	07-14-1998	Brent et al.	
A121		5,780,483	07-14-1998	Widdowson et al.	
A122		5,783,664	07-21-1998	Lee et al.	
A123		5,786,362	07-28-1998	Krongrad	
A123a		5,801,794	09-01-1998	Lehureau et al.	
A124		5,807,876	09-15-1998	Armistead et al.	
A125		5,807,891	09-15-1998	Bold et al.	
A126		5,808,080	09-15-1998	Bell et al.	
A127		5,814,646	09-29-1998	Heinz et al.	
A128		5,869,043	02-09-1999	McDonnell et al.	
A129		5,871,934	02-16-1999	Lee et al.	
A130		5,886,044	03-23-1999	Widdowson et al.	
A131		5,891,895	04-06-1999	Shiraishi et al.	
A132		5,908,865	06-01-1999	Dci et al.	
A133		5,919,773	07-06-1999	Monia et al.	
A134		5,929,250	07-27-1999	Widdowson et al.	
A135		5,955,366	09-21-1999	Lee et al.	
A136		5,965,573	10-12-1999	Petrie et al.	
A137		6,004,965	12-21-1999	Breu et al.	
A138		6,005,008	12-21-1999	Widdowson et al.	
A139		6,015,908	01-18-2000	Widdowson et al.	
A140		6,017,692	01-25-2000	Brent et al.	
A141		6,020,345	02-01-2000	Vacher et al.	
A142		6,022,884	02-08-2000	Mantlo et al.	
A143		6,025,151	02-15-2000	Peterson	
A144		6,033,873	03-07-2000	McDonnell et al.	
A145		6,040,339	03-21-2000	Yoshida et al.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of 37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
A110		5,656,612		08-12-1997	Monia	
A111		5,658,903		08-19-1997	Adams et al.	
A146		6,043,374		03-28-2000	Widdowson et al.	
A147		6,080,763		06-27-2000	Regan et al.	
A148		6,093,742		07-25-2000	Saitturo et al.	
A149		6,103,692		08-15-2000	Avruch et al.	
A150		6,114,517		09-05-2000	Monia et al.	
A151		6,130,053		10-10-2000	Thompson et al.	
A152		6,133,319		10-17-2000	Widdowson	
A153		6,136,779		10-24-2000	Foulkes et al.	
A154		6,143,764		11-07-2000	Kubo et al.	
A155		6,147,107		11-14-2000	Dent et al.	
A156		6,147,116		11-14-2000	Barbachyn et al.	
A157		6,150,415		11-21-2000	Harmmock et al.	
A157a		6,159,901		12-12-2000	Kanno et al.	
A158		6,174,901		01-16-2001	Mantlo et al.	
A159		6,177,401		01-23-2001	Ullrich et al.	
A160		6,178,399		01-23-2001	Takebayashi et al.	
A161		6,180,631		01-30-2001	McMahon et al.	
A162		6,180,675		01-30-2001	Widdowson et al.	
A163		6,187,799		02-13-2001	Wood et al.	
A164		6,193,965		02-27-2001	Karin et al.	
A165		6,204,267		03-20-2001	Tang et al.	
A166		6,210,710		04-03-2001	Skinner	
A167		6,211,373		04-03-2001	Widdowson et al.	
A168		6,218,539		04-17-2001	Widdowson	
A169		6,228,881		05-08-2001	Regan et al.	
A170		6,235,764		05-22-2001	Larson et al.	
A170a		6,236,125		05-22-2001	Oudet et al.	
A171		6,242,601		06-05-2001	Breu et al.	
A172		6,262,113		07-17-2001	Widdowson et al.	
A173		6,271,261		08-07-2001	Widdowson	
A174		6,294,350		09-25-2001	Peterson	
A175		6,297,381		10-02-2001	Cirillo et al.	
A176		6,310,068		10-30-2001	Böttcher et al.	
A177		6,316,462		11-13-2001	Bishop et al.	
A178		6,319,921		11-20-2001	Cirillo et al.	
A179		6,329,415		12-11-2001	Cirillo et al.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A180		6,333,341	12-25-2001	Mantlo et al.	
A181		6,339,045	01-15-2002	Kanno et al.	
A182		6,344,476	02-05-2002	Ranges et al.	
A183		6,352,977	03-05-2002	Astles et al.	
A184		6,358,525	03-19-2002	Guo et al.	
A185		6,358,945	03-19-2002	Breitfelder et al.	
A186		6,361,773	03-26-2002	Lee et al.	
A187		6,372,773	04-16-2002	Regan	
A188		6,372,933	04-16-2002	Baine et al.	
A189		6,380,218	04-30-2002	Marfat et al.	
A190		6,383,734	05-07-2002	Marshall et al.	
A191		6,387,900	05-14-2002	Pevarelio et al.	
A192		6,391,917	05-21-2002	Petrie et al.	
A193		6,403,588	06-11-2002	Hayakawa et al.	
A194		6,414,011	07-02-2002	Hogenkamp et al.	
A195		6,444,691	09-03-2002	Oremus et al.	
A196		6,448,079	09-10-2002	Monia et al.	
A197		6,479,519	11-12-2002	Astles et al.	
A198		6,492,393	12-10-2002	Breitfelder et al.	
A199		6,495,331	12-17-2002	Gelfand et al.	
A200		6,500,863	12-31-2002	Jin et al.	
A201		6,511,800	01-28-2003	Singh	
A202		6,511,997	01-28-2003	Minami et al.	
A203		6,521,407	02-18-2003	Warenius et al.	
A204		6,521,592	02-18-2003	Ko et al.	
A205		6,524,832	02-25-2003	Kufe et al.	
A206		6,525,046	02-25-2003	Cirillo et al.	
A207		6,525,065	02-25-2003	Caldwell et al.	
A208		6,525,091	02-25-2003	Robinson et al.	
A209		6,583,282	06-24-2003	Zhang et al.	
A210		6,608,052	08-19-2003	Breitfelder et al.	
A211		6,617,324	09-09-2003	Naraian et al.	
A212		6,635,421	10-21-2003	Klagsbrun et al.	
A213		6,653,320	11-25-2003	Hayakawa et al.	
A214		6,656,963	12-02-2003	Firestone et al.	
A215		6,673,777	01-06-2004	Tracey et al.	
A216		6,689,560	02-10-2004	Rapp et al.	
A217		6,797,823	09-28-2004	Kubo et al.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A217a		6,958,333	10-25-2005	Hayama et al.	
A218		7,070,968	07-04-2006	Kufe et al.	
A219		7,235,576	06-26-2007	Riedl et al.	
A220		7,253,286	06-07-2007	Funahashi et al.	
A221		7,307,071	12-11-2007	Lyons et al.	
A222		7,329,670	02-12-2008	Dumas et al.	
A223		7,351,634	04-01-2008	Riedl et al.	
A224		7,371,763	05-13-2008	Dumas et al.	
A225		7,517,880	04-14-2009	Miller et al.	
A226		7,528,255	05-05-2009	Riedl et al.	
A226a		7,547,695	06-16-2009	Hoelzemann et al.	
A227		7,557,129	07-07-2009	Scott et al.	
A227a		7,605,261	10-20-2009	Deprez et al.	
A227b		7,612,092	11-03-2009	Funahashi et al.	
A228		7,678,811	03-16-2010	Dumas et al.	
B1		2001/0006975	07-05-2001	Wood et al.	
B2		2001/0011135	08-02-2001	Riedl et al.	
B3		2001/0011136	08-02-2001	Riedl et al.	
B4		2001/0016659	08-23-2001	Riedl et al.	
B5		2001/0027202	10-04-2001	Riedl et al.	
B6		2001/0034447	10-25-2001	Riedl et al.	
B7		2001/0038842	11-08-2001	Achen et al.	
B8		2002/0037276	03-28-2002	Ptasznik et al.	
B9		2002/0042517	04-11-2002	Uday et al.	
B10		2002/0082763	05-30-2002	Macholdt et al.	
B11		2002/0065283	05-30-2002	McMahon et al.	
B12		2002/0065296	05-30-2002	Dumas et al.	
B13		2002/0082255	06-27-2002	Eastwood	
B14		2002/0085857	07-04-2002	Kim et al.	
B15		2002/0085859	07-04-2002	Hashimoto et al.	
B16		2002/0103253	08-01-2002	Ranges et al.	
B16a		2002/0111495	08-15-2002	Magee et al.	
B17		2002/0128321	09-12-2002	Widdowson et al.	
B18		2002/0137774	09-26-2002	Riedl et al.	
B19		2002/0161014	10-31-2002	Sadhu et al.	
B20		2002/0165275	11-07-2002	Wu et al.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

8

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
B21		2002/0165349	11-07-2002	Kirsch et al.	
B22		2002/0165394	11-07-2002	Dumas et al.	
B23		2002/0173507	11-21-2002	Santora et al.	
B24		2002/0188027	12-12-2002	Robinson et al.	
B25		2002/0197256	12-26-2002	Grewal	
B26		2003/0069284	04-10-2003	Keegan et al.	
B26a		2003/0105091	06-05-2003	Riedl et al.	
B27		2003/0125359	07-03-2003	Lyons et al.	
B28		2003/0130309	07-10-2003	Moss et al.	
B29		2003/0144278	07-31-2003	Riedl et al.	
B30		2003/0157104	08-21-2003	Waksal	
B30a		2003/0139605	07-24-2003	Riedl et al.	
B31		2003/0181442	09-25-2003	Riedl et al.	
B32		2003/0207870	11-06-2003	Dumas et al.	
B33		2003/0207872	11-06-2003	Riedl et al.	
B34		2003/0207914	11-06-2003	Dumas et al.	
B34a		2003/0216396	11-20-2003	Dumas et al.	
B35		2003/0216446	11-20-2003	Dumas et al.	
B36		2003/0232400	12-18-2003	Radka et al.	
B37		2003/0232765	12-18-2003	Carter et al.	
B37a		2004/0023961	02-05-2004	Dumas et al.	
B38		2004/0052880	03-18-2004	Kobayashi et al.	
B39		2004/0096855	05-20-2004	Stratton et al.	
B40		2004/0147541	07-29-2004	Lane et al.	
B41		2004/0192770	09-30-2004	Kozikowski et al.	
B42		2004/0197256	10-07-2004	Rogers et al.	
B43		2004/0209905	10-21-2004	Kubo et al.	
B43a		2004/0224937	11-11-2004	Furness et al.	
B44		2004/0229937	11-18-2004	Dumas et al.	
B45		2004/0235829	11-25-2004	Scott et al.	
B46		2005/0032798	02-10-2005	Boyer et al.	
B47		2005/0038031	02-17-2005	Dumas et al.	
B48		2005/0038080	02-17-2005	Boyer et al.	
B49		2005/0059703	03-17-2005	Wilhelm et al.	
B49a		2005/0069963	03-31-2005	Lokshin et al.	
B49b		2005/0096344	05-05-2005	Fraley et al.	
B49c		2005/0175737	06-11-2005	Knobel	
B50		2005/0256174	11-17-2005	Wood et al.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

9

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
B51		2005/0288286	12-29-2005	Flynn et al.	
B52		2006/0058358	03-16-2006	Dumas et al.	
B52a		2006/0241301	10-26-2006	Hoelzemann et al.	
B52b		2006/0281762	12-14-2006	Staehle et al.	
B53		2006/0078617	04-13-2006	Schueckler	
B54		2006/0211738	09-21-2006	Mitchell et al.	
B55		2006/0234931	10-19-2006	Biggs, III et al.	
B56		2006/0247186	11-02-2006	Carter et al.	
B57		2007/0020704	01-25-2007	Wilhelm et al.	
B58		2007/0105142	05-10-2007	Wilhelm	
B60		2007/0178494	06-02-2007	Elting et al.	
B61		2007/0244120	10-18-2007	Dumas et al.	
B62		2007/0265315	11-15-2007	Dumas et al.	
B63		2008/0009527	01-10-2008	Dumas et al.	
B64		2008/0027061	01-31-2008	Riedl et al.	
B65		2008/0032979	02-07-2008	Riedl et al.	
B67		2008/0045589	02-21-2008	Kelley	
B69		2008/0108672	05-08-2008	Riedl et al.	
B70		2008/0153823	06-26-2008	Riedl et al.	
B71		2008/0194580	08-14-2008	Dumas et al.	
B72		2008/0214545	09-04-2008	Lee et al.	
B73		2008/0227828	09-18-2008	Dumas et al.	
B74		2008/0242707	10-02-2008	Schuckler et al.	
B76		2008/0269265	10-30-2008	Miller et al.	
B77		2008/0300281	12-04-2008	Dumas et al.	
B77a		2008/0311601	12-18-2008	Elting et al.	
B77b		2008/0311604	12-18-2008	Elting et al.	
B78		2009/0068146	03-12-2009	Wilhelm	
B79		2009/0093526	04-09-2009	Miller et al.	
B80		2009/0118268	05-07-2009	Riedl et al.	
B82		2009/0192127	07-30-2009	Scheuring et al.	
B84		2009/0215835	08-27-2009	Wilhelm	
B84a		2009/0221010	09-03-2009	Elting et al.	
B85		2009/0227637	09-10-2009	Weber et al.	
B86		2009/0306020	12-10-2009	Scheuring et al.	
B88		2010/0063088	03-11-2010	Wood et al.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

10

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C1	WO-90/02112	03-08-1990	The Nutrasweet Company		
	C2	WO-92/03413	03-05-1992	Rhone-Rouenc Rorer Limited et al.		
	C3	WO-92/05179	04-02-1992	American Home Products Corporation		
	C4	WO-93/04170	03-04-1993	The United States of America represented by The Secretary, Department Of Health And Human Services		
	C5	WO-93/18028	09-16-1993	SmithKline Beecham PLC et al.		
	C6	WO-93/24458	12-09-1993	Pfizer Inc. et al.		
	C7	WO-94/02136	02-03-1994	SmithKline Beecham Corp. et al.		
	C8	WO-94/02485	02-03-1994	SmithKline Beecham Corp. et al.		
	C9	WO-94/04541	03-03-1994	The UpJohn Co. et al.		
	C10	WO-94/14801	07-07-1994	SmithKline Beecham PLC et al.		
	C11	WO-94/18170	08-18-1994	SmithKline Beecham PLC et al.		
	C12	WO-94/22807	10-13-1994	Neu-Research, A/S et al.		
	C13	WO-94/23755	10-27-1994	Board of Regents of the University of Nebraska		
	C14	WO-94/25012	11-10-1994	SmithKline Beecham PLC et al.		
	C15	WO-95/02136	01-19-1995	Mannesmann Aktiengesellschaft		abs

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C16	WO-95/02591	01-26-1995	SmithKline Beecham Corporation et al.		
	C17	WO-95/07922	03-23-1995	SmithKline Beecham Corporation et al.		
	C18	WO-95/13067	05-18-1995	SmithKline Beecham Corporation et al.		
	C19	WO-95/14023	05-26-1995	Abbott Laboratories		
	C20	WO-95/16691	06-22-1995	Sandoz Ltd. et al.		
	C21	WO-95/19169	07-20-1995	Sugen, Inc.		
	C22	WO-95/31451	11-23-1995	SmithKline Beecham Corporation et al.		
	C23	WO-95/33458	12-14-1995	SmithKline Beecham Corporation et al.		
	C24	WO-95/33460	12-14-1995	SmithKline Beecham Corporation et al.		
	C25	WO-96/02112	01-25-1996	Thomson-CSF et al.		abs
	C26	WO-96/10559	04-11-1996	Fujisawa Pharmaceutical Co., Ltd.		
	C27	WO-96/13632	05-09-1996	Novo Nordisk A/S et al.		
	C28	WO-96/25157	08-22-1996	Smith Kline Beecham Corporation et al.		
	C29	WO-96/40673	12-19-1996	Sugen, Inc.		
	C30	WO-96/40675	12-19-1996	Sugen, Inc.		
	C31	WO-96/41807	12-27-1996	Sandoz Ltd. et al.		
	C32	WO-97/03069	01-30-1997	Glaxo Group Limited et al.		
	C33	WO-97/09973	03-20-1997	The Regents of The University of California et al.		
	C34	WO-97/17267	05-15-1997	SCA Mölnlycke AB et al.		
	C35	WO-97/17329	05-15-1997	Kirin Beer Kabushiki Kaisha		abs

Examiner Signature	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	12	of	37	Attorney Docket Number	BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C36	WO-97/29743	08-21-1997	Smith Kline Beecham Corporation et al.		
	C37	WO-97/30992	08-28-1997	Bristol-Myers Squibb Company		
	C38	WO-97/34146	09-18-1997	The General Hospital Corporation		
	C39	WO-97/40028	10-30-1997	Vertex Pharmaceuticals Incorporated		
	C40	WO-97/40842	11-06-1997	Eli Lilly and Company et al.		
	C41	WO-97/45400	12-04-1997	Neu-Research A/S et al.		
	C42	WO-97/49399	12-31-1997	SmithKline Beecham Corporation et al.		
	C43	WO-97/49400	12-31-1997	SmithKline Beecham Corporation et al.		
	C44	WO-98/17207	04-30-1998	Synthes AG Chur et al.		
	C45	WO-98/17267	04-30-1998	ZymoGenetics, Inc. et al.		
	C46	WO-98/20868	05-22-1998	The Picower Institute for Medical Research		
	C47	WO-98/22103	05-28-1998	Zeneca Limited et al.		
	C48	WO-98/22432	05-28-1998	Yamanouchi Pharmaceutical Co., Ltd.		abs
	C49	WO-98/32439	07-30-1998	SmithKline Beecham Corporation et al.		
	C50	WO-98/34929	08-13-1998	SmithKline Beecham Corporation et al.		
	C51	WO-98/45268	10-15-1998	Pfizer Products Inc. et al.		
	C52	WO-98/49150	11-05-1998	Takeda Chemical Industries, Ltd. et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

13

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C53	WO-98/52558	11-26-1998	Bayer Corporation et al.		
	C54	WO-98/52559	11-26-1998	Bayer Corporation et al.		
	C55	WO-98/52937	11-26-1998	G.D. Searle and Co. et al.		
	C56	WO-98/52941	11-26-1998	G.D. Searle and Co. et al.		
	C57	WO-98/56377	12-17-1998	SmithKline Beecham Corporation et al.		
	C58	WO-99/00357	01-07-1999	Vertex Pharmaceuticals Incorporated		
	C59	WO-99/00370	01-07-1999	Kureha Kagaku Kogyo Kabushiki Kaisha		abs
	C60	WO-99/20617	04-29-1999	Pharmacia & UpJohn Company et al.		
	C61	WO-99/21835	05-06-1999	Fujisawa Pharmaceutical Co., Ltd. et al.		
	C62	WO-99/23091	05-14-1999	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C63	WO-99/24035	05-20-1999	Bristol-Myers Squibb Company		
	C64	WO-99/24398	05-20-1999	Zeneca Limited et al.		
	C65	WO-99/24635	05-20-1999	Advanced Technology Materials, Inc.		
	C66	WO-99/26657	06-03-1999	Medical University of South Carolina et al.		
	C67	WO-99/28305	06-10-1999	E.I. DuPont De Nemours & Company et al.		
	C68	WO-99/32106	07-01-1999	Bayer Corporation		
	C69	WO-99/32109	07-01-1999	Bristol-Myers Squibb Company		
	C70	WO-99/32110	07-01-1999	Bayer Corporation		
	C71	WO-99/32111	07-01-1999	Bayer Corporation		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

14

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C72	WO-99/32436	07-01-1999	Bayer Corporation		
	C73	WO-99/32437	07-01-1999	Slovako-Farma, A.S. et al.		
	C74	WO-99/32455	07-01-1999	Bayer Corporation		
	C75	WO-99/32463	07-01-1999	Bayer Corporation		
	C76	WO-99/33458	07-08-1999	Daiichi Pharmaceuticals Co., Ltd. et al.		abs
	C77	WO-99/35132	07-15-1999	Glaxo Group Limited et al.		
	C78	WO-99/40673	08-12-1999	Moving Magnet Technologies (S.A.) et al.		abs
	C79	WO-99/58502	11-18-1999	Vertex Pharmaceuticals Incorporated et al.		
	C80	WO-99/62890	12-09-1999	Pfizer Products Inc. et al.		
	C81	WO-00/12497	03-09-2000	Scios Inc. et al.		
	C82	WO-00/17175	03-30-2000	Vertex Pharmaceuticals Incorporated et al.		
	C83	WO-00/19205	04-06-2000	Advanced Research and Technology Institute, Inc. et al.		
	C84	WO-00/26203	05-11-2000	Pharmacia & UpJohn S.P.A. et al.		
	C85	WO-00/27414	05-18-2000	BASF Aktiengesellschaft et al.		
	C86	WO-00/31238	06-02-2000	Genetica, Inc. et al.		
	C87	WO-00/34303	06-15-2000	Isis Pharmaceuticals, Inc. et al.		
	C88	WO-00/35454	06-22-2000	Du Pont Pharmaceuticals Company		
	C89	WO-00/35455	06-22-2000	Telik, Inc.		
	C90	WO-00/39101	07-06-2000	Astra Zeneca UK Limited et al.		
	C91	WO-00/39116	07-06-2000	Teikoku Hormone MFG. Co., Ltd.		abs

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

15

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C92	WO-00/41698	07-20-2000	Bayer Corporation et al.		
	C93	WO-00/42012	07-20-2000	Bayer Corporation et al.		
	C94	WO-00/43366	07-27-2000	Kirin Beer Kabushiki Kaisha		abs
	C95	WO-00/43384	07-27-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C96	WO-00/47577	08-17-2000	SmithKline Beecham PLC et al.		
	C97	WO-00/50425	08-31-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C98	WO-00/55139	09-21-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C99	WO-00/55152	09-21-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C100	WO-00/56331	09-28-2000	Vertex Pharmaceuticals Incorporated et al.		
	C101	WO-00/71506	11-30-2000	Telik, Inc.		
	C102	WO-00/71532	11-30-2000	Pfizer Products Inc. et al.		
	C103	WO-01/04115	01-18-2001	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C104	WO-01/07411	02-01-2001	Banyu Pharmaceutical Co., Ltd.		abs
	C105	WO-01/09088	02-08-2001	Kirin Beer Kabushiki Kaisha et al.		
	C106	WO-01/12188	02-22-2001	Pharmacia & UpJohn S.P.A. et al.		

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

16

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C107	WO-01/36403	05-25-2001	Boehringer Ingelheim Pharmaceuticals, Inc. et al.		
	C108	WO-01/47892	07-05-2001	American Home Products Corporation		
	C109	WO-01/54723	08-02-2001	Sunnybrook Health Science Center et al.		
	C110	WO-01/54727	08-02-2001	The Van Kampen Group, Inc. et al.		
	C111	WO-01/57008	08-09-2001	BASF Aktiengesellschaft et al.		
	C112	WO-01/63403	08-30-2001	Sun Microsystems, Inc.		
	C113	WO-01/66099	09-13-2001	Astra Zeneca AB et al.		
	C114	WO-01/66540	09-13-2001	SmithKline Beecham P.L.C. et al.		
	C114a	WO-01/80843	11-01-2001	Supergen, Inc. et al.		
	C115	WO-02/06382	01-24-2002	General Electric Company		
	C116	WO-02/07747	01-31-2002	Joslin Diabetes Center, Inc. et al.		
	C117	WO-02/07772	01-31-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C118	WO-02/10141	02-07-2002	Pfizer Products Inc. et al.		
	C119	WO-02/14281	02-21-2002	Cochran et al.		
	C120	WO-02/14311	02-21-2002	Amgen Inc. et al.		
	C121	WO-02/18346	03-07-2002	Pfizer Products Inc. et al.		
	C122	WO-02/24635	03-28-2002	Fujisawa Pharmaceutical Co., Ltd. et al.		
	C123	WO-02/25286	03-28-2002	The President and Fellows of Harvard College		
	C124	WO-02/32872	04-25-2002	Eisai Co., Ltd.		abs
	C125	WO-02/40445	05-23-2002	Novo Nordisk A/S		
	C126	WO-02/42012	05-30-2002	Brill		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

17

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C127	WO-02/44156	06-06-2002	Glaxo Group Limited et al.		
	C128	WO-02/44158	06-06-2002	Pfizer Products Inc. et al.		
	C129	WO-02/50091	06-27-2002	Glaxo Group Limited et al.		
	C130	WO-02/059081	08-01-2002	Padia et al.		
	C131	WO-02/059102	08-01-2002	Aventis Pharma S.A. et al.		abs
	C132	WO-02/060900	08-08-2002	Telik, Inc. et al.		
	C133	WO-02/062763	08-15-2002	Bayer Corporation et al.		
	C134	WO-02/070008	09-12-2002	Imclone Systems Incorporated et al.		
	C135	WO-02/076930	10-03-2002	Telik, Inc.		
	C136	WO-02/076977	10-03-2002	Bayer Corporation et al.		
	C137	WO-02/083628	10-24-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C138	WO-02/083642	10-24-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C139	WO-02/085657	10-31-2002	Bayer Corporation et al.		
	C140	WO-02/085859	10-31-2002	Bayer Corporation et al.		
	C141	WO-02/088090	11-07-2002	Vertex Pharmaceuticals Incorporated et al.		
	C142	WO-02/092576	11-21-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C143	WO-03/004523	01-16-2003	Bayer Aktiengesellschaft et al.		
	C144	WO-03/005999	01-23-2003	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C145	WO-03/047523	06-12-2003	Onyx Pharmaceuticals, Inc.		
	C146	WO-03/047579	06-12-2003	Bayer Corporation et al.		

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

18

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C147	WO-03/056036	07-10-2003	Catalyst Biomedica Limited et al.		
	C148	WO-03/059373	07-24-2003	Ramot at Tel Aviv University Ltd. et al.		
	C149	WO-03/060111	07-24-2003	Catalyst Biomedica Limited et al.		
	C150	WO-03/065995	08-14-2003	Supergen, Inc. et al.		
	C151	WO-03/068223	08-21-2003	Bayer Corporation et al.		
	C152	WO-03/068228	08-21-2003	Bayer Corporation et al.		
	C153	WO-03/068229	08-21-2003	Bayer Corporation et al.		
	C154	WO-03/068746	08-21-2003	Bayer Corporation et al.		
	C155	WO-03/082272	10-09-2003	Chiron Corporation et al		
	C156	WO-03/094626	11-20-2003	KMB Produktions AG et al.		abs
	C156a	WO-03/097854	11-27-2003	Sugen, Inc. et al.		
	C157	WO-03/099771	12-04-2003	Novartis AG et al.		
	C158	WO-2004/004720	01-15-2004	Astex Technology Limited et al.		
	C159	WO-2004/019941	03-11-2004	MERCK PATENT GMBH et al.		
	C160	WO-2004/037789	05-06-2004	MERCK PATENT GMBH et al.		
	C161	WO-2004/043374	05-27-2004	Dana-Farber Cancer Institute Inc. et al.		
	C162	WO-2004/045578	06-03-2004	NOVARTIS AG et al.		
	C163	WO-2004/052880	06-24-2004	ASTRAZENECA AB et al.		
	C164	WO-2004/078128	09-16-2004	Bayer Pharmaceuticals Corporation et al.		
	C165	WO-2004/078746	09-16-2004	Bayer Pharmaceuticals Corporation et al.		
	C166	WO-2004/078747	09-16-2004	Bayer Pharmaceuticals Corporation et al.		
	C167	WO-2004/078748	09-16-2004	Bayer Pharmaceuticals Corporation et al.		

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	19	of	37	Attorney Docket Number	BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C168	WO-2004/085399	10-07-2004	MERCK PATENT GMBH et al.		
	C169	WO-2004/085425	10-07-2004	AMGEN INC.		
	C170	WO-2004/108713	12-16-2004	Warner-Lambert Company LLC et al.		
	C171	WO-2004/108715	12-16-2004	Warner-Lambert Company LLC et al.		
	C172	WO-2004/113274	12-29-2004	Bayer Pharmaceuticals Corporation et al.		
	C173	WO-2005/000284	01-06-2005	Bayer Pharmaceuticals Corporation et al.		
	C174	WO-2005/002673	01-13-2005	Astex Technology Limited et al.		
	C175	WO-2005/004863	01-20-2005	MERCK PATENT GMBH et al.		
	C176	WO-2005/004864	01-20-2005	MERCK PATENT GMBH et al.		
	C177	WO-2005/005389	01-20-2005	MERCK PATENT GMBH et al.		
	C178	WO-2005/005434	01-20-2005	NOVARTIS AG et al.		
	C179	WO-2005/009367	02-03-2005	AMBIT BIOSCIENCES CORPORATION et al.		
	C180	WO-2005/009961	02-03-2005	Bayer Pharmaceuticals Corporation et al.		
	C181	WO-2005/011700	02-10-2005	SMITHKLINE BEECHAM CORPORATION et al.		
	C182	WO-2005/016252	02-24-2005	Ariad Gene Therapeutics, Inc. et al.		
	C183	WO-2005/019192	03-03-2005	MERCK PATENT GMBH et al.		abs
	C184	WO-2005/032548	04-14-2005	CHIRON CORPORATION et al.		
	C185	WO-2005/037273	04-28-2005	CHIRON CORPORATION et al.		
	C186	WO-2005/037285	04-28-2005	CHIRON CORPORATION et al.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

20

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C187	WO-2005/037829	04-28-2005	MERCK PATENT GMBH et al.		abs
	C188	WO-2005/042520	05-12-2005	MERCK PATENT GMBH et al.		abs
	C189	WO-2005/047283	05-26-2005	MERCK PATENT GMBH et al.		abs
	C190	WO-2005/048948	06-02-2005	Ambit Biosciences Corporation et al.		
	C191	WO-2005/049603	06-02-2005	MERCK PATENT GMBH et al.		abs
	C191a	WO-2005/056764	06-23-2005	Compound Therapeutics, Inc. et al.		
	C192	WO-2005/058832	06-30-2005	MERCK PATENT GMBH et al.		
	C192a	WO-2005/059179	06-30-2005	Bayer Pharmaceutical Corporation et al.		
	C193	WO-2005/075425	08-18-2005	MERCK PATENT GMBH et al.		
	C194	WO-2005/089443	09-29-2005	The Penn State Research Foundation et al.		
	C195	WO-2005/110994	11-24-2005	Bayer Pharmaceuticals Corporation et al.		
	C196	WO-2006/026500	03-09-2006	Bayer Pharmaceuticals Corporation et al.		
	C197	WO-2006/026501	03-09-2006	Bayer Pharmaceuticals Corporation et al.		
	C198	WO-2006/027346	03-16-2006	ALTANA PHARMA AG et al.		
	C199	WO-2006/034797	04-06-2006	BAYER HEALTHCARE AG et al.		
	C200	WO-2006/094626	09-14-2006	BAYER HEALTHCARE AG et al.		
	C201	WO-2006/105844	10-12-2006	MERCK PATENT GMBH et al.		abs
	C202	WO-2006/125540	11-30-2006	BAYER HEALTHCARE AG et al.		
	C203	WO-2007/015947	02-08-2007	BAYER HEALTHCARE LLC et al.		
	C204	WO-2007/039403	04-12-2007	ALTANA PHARMA AG et al.		

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	21	of	37	Attorney Docket Number	BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	C205	WO-2007/039404	04-12-2007	ALTANA PHARMA AG et al.		
	C205a	WO-2007/047955	04-26-2007	BAYER HEALTHCARE LLC et al.		
	C206	WO-2007/053573	05-10-2007	Bayer Pharmaceuticals Corporation et al.		
	C207	WO-2007/054215	05-18-2007	BAYER HEALTHCARE AG et al.		
	C207a	WO-2007/056011	05-18-2007	BAYER HEALTHCARE LLC et al.		
	C207b	WO-2007/056012	05-18-2007	BAYER HEALTHCARE LLC et al.		
	C208	WO-2007/059094	05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C209	WO-2007/059154	05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C210	WO-2007/059155	05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C211	WO-2007/064872	06-07-2007	Bayer Pharmaceuticals Corporation et al.		
	C215	WO-2007/123722	11-01-2007	Bayer Pharmaceuticals Corporation et al.		
	C216	WO-2007/139930	12-06-2007	Bayer Pharmaceuticals Corporation et al.		
	C218	WO-2008/079968	07-03-2008	Bayer Pharmaceuticals Corporation et al.		
	C219	WO-2008/079972	07-03-2008	Bayer Pharmaceuticals Corporation et al.		
	C220	WO-2008/089389	07-24-2008	Bayer Pharmaceuticals Corporation et al.		
	D1	EP-0016371	10-01-1980	F. Hoffman-La Roche & Co. Aktiengesellschaft		abs

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	22	of	37	Attorney Docket Number	BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	D2	EP-0107214	05-02-1984	Duphar International Research B.V.		
	D3	EP-0116932	08-29-1984	BASF Aktiengesellschaft		abs
	D3a	EP-0192263	07-29-1992	Ishihara Sangyo Kaisha Ltd. et al.		
	D4	EP-0192263	08-27-1986	Ishihara Sangyo Kaisha Ltd. et al.		
	D5	EP-0202538	11-26-1986	Bayer AG		abs
	D6	EP-0230400	07-29-1987	CIBA-GEIGY AG		abs
	D6a	EP-0233559	08-26-1987	Ishihara Sangyo Kaisha Ltd. et al.		
	D7	EP-0233559	05-06-1992	Ishihara Sangyo Kaisha Ltd. et al.		
	D8	EP-0242666	10-28-1987	BASF Aktiengesellschaft		abs
	D9	EP-0264904	04-27-1988	Ishihara Sangyo Kaisha Ltd. et al.		
	D10	EP-0314615	05-03-1989	Ciba-Geigy AG		abs
	D11	EP-0335156	10-04-1989	Bayer AG		abs
	D12	EP-0359148	03-21-1990	Ishihara Sangyo Kaisha, Ltd. et al.		
	D13	EP-0371876	06-06-1990	Novapharme		abs
	D14	EP-0379915	08-01-1990	Bayer AG		abs
	D15	EP-0380048	08-01-1990	Ishihara Sangyo Kaisha, Ltd.		
	D16	EP-0381987	08-16-1990	Ishihara Sangyo Kaisha, Ltd. et al.		
	D17	EP-0405233	01-02-1991	Mitsubishi Kasei Corporation		
	D18	EP-0425443	05-02-1991	Ciba-Geigy AG		abs
	D19	EP-0459887	12-04-1991	Novapharme		abs
	D20	EP-0502504	09-09-1992	Matsushita Electric Industrial Co., Ltd.		
	D21	EP-0509795	10-21-1992	American Home Products Corporation		
	D22	EP-0676395	10-11-1995	Hoechst Aktiengesellschaft		abs
	D23	EP-0690344	01-03-1996	Konica Corporation		
	D24	EP-0709220	05-01-1996	Canon Kabushiki Kaisha		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	23	of	37	Attorney Docket Number	BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	D248	EP-0709225	05-01-1996	Nippon Paper Industries Co., Ltd.		
	D25	EP-0709225	08-05-1998	Nippon Paper Industries Co., Ltd.		
	D26	EP-0860433	08-26-1998	Kirin Beer Kabushiki Kaisha		
	D27	EP-1056725	12-06-2000	Bayer Corporation		
	D28	EP-1199306	04-24-2002	Banyu Pharmaceutical Co., Ltd.		
	D29	EP-1256587	11-13-2002	The Kitasato Institute		
	D30	EP-1537075	06-08-2005	Neurosearch A/S et al.		
	E1	CH-479557	11-28-1969	Dr. A. Wander AG		abs
	F1	CL-38688	06-04-1993	Ciba-Geigy AG		
	G1	CA-2 146 707	10-12-1995	Hoechst Aktiengesellschaft		
	G2	CA-2,028,536	04-28-1991	Ciba-Geigy AG		
	H1	DD-253997	02-10-1988	Karl-Marx-Universität Büro Für Neuerungen und Schutzrechte		abs
	I1	DE-487014	11-14-1929	I.G. Farbenindustrie Akt.-Ges.		
	I2	DE-511468	10-16-1930	I.G. Farbenindustrie Akt.-Ges.		abs
	I3	DE-523437	04-02-1931	I.G. Farbenindustrie Akt.-Ges.		
	I4	DE-2436179	04-10-1986	Shionogi & Co. Ltd.		abs
	I5	DT-2501648	07-24-1975	The Dow Chemical Co.		abs
	I6	DT-2436179	02-06-1975	Shionogi & Co., Ltd.		abs
	I7	DE-3305866	08-23-1984	BASF AG		abs
	I8	DE-3529247	11-20-1986	Bayer AG		abs
	I9	DE-3540377	05-21-1987	Bayer AG		abs
	J1	FR-1,457,172	09-19-1966	Ferrania S.p.A.		abs
	K1	GB-771,333	03-27-1957	J.R. Geigy A.-G.		
	K2	GB-828,231	02-17-1960	J.R. Geigy A.-G.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

24

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	K3	GB-921,682	03-20-1963	J.R. Geigy A.-G.		
	K4	GB-1,110,099	04-18-1968	Rhone- Poulenc S.A.		
	K4a	GB-1,111,554	05-01-1968	Societa Per Azioni Ferrania		
	K5	GB-1 590 870	06-10-1981	Shionogi Seiyaku Kabushiki Kaisha.		
	L1	HU-P0004437	06-28-2001	Bayer Corporation		abs
	M1	IR-26555	01-13-2000	Bayer Corporation		abs
	N1	JP-44-2569	02-03-1969	Sankyo Co., Ltd. and Asahi Chem. Ind. Co., Ltd		abs
	N2	JP-50-76072	06-21-1975	Shionogi Seiyaku KK		abs
	N3	JP-50-77375	06-24-1975	Shionogi Seiyaku KK		abs
	N4	JP-50-149668	11-29-1975	unknown		abs
	N5	JP-51-63170	06-01-1976	Shionogi Shinzaburo		abs
	N6	JP-51-60862	07-15-1976	Shionogi Seiyaku KK		abs
	N7	JP-53-86033	07-29-1978	Shionogi Co. Ltd.		abs
	N8	JP-54-32468	09-03-1979	Otsuka Pharmaceutical Co. Ltd.		abs
	N9	JP-55-98152	07-25-1980	HOKKO CHEM. IND. CO.		abs
	N10	JP-55-124763	09-26-1980	Ishihara Mining & Chemical Co.		abs
	N11	JP-55-162772	12-18-1980	Shionogi & Co. Ltd.		abs
	N13	JP-57-53785	11-15-1982	Shionogi Seiyaku KK		abs
	N14	JP-58-21626	05-02-1983	Shionogi Seiyaku KK		abs
	N16	JP-61-20039	01-28-1985	Konishiroku Photo Ind. Co., Ltd.		abs
	N15	JP-63-214752	09-07-1988	Fuji Photo Film Co. Ltd.		abs
	N17	JP-64-9455	01-12-1989	Fuji Photo Film Co., Ltd.		abs
	N18	JP-1-102461	04-20-1989	Konica Corp.		abs
	N19	JP-1-132580	05-25-1989	Ciba Geigy AG		abs
	N20	JP-1-200254	08-11-1989	Konica Corp.		abs

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	25	of	37	Attorney Docket Number	BAYER-0044

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	N21	JP-1-259360	10-17-1989	Konica Corp.		abs
	N22	JP-2-22650	01-25-1990	Konica Corp.		abs
	N23	JP-2-23337	01-25-1990	Konica Corp.		abs
	N24	JP-2-35450	02-06-1990	Konica Corp.		abs
	N25	JP-2-105146	04-17-1990	Konica Corp.		abs
	N26	JP-2-108048	04-19-1990	Konica Corp.		abs
	N27	JP-2-150840	06-11-1990	Konica Corp.		abs
	N28	JP-3-53247	03-07-1991	Fuji Photo Film Co. Ltd.		abs
	N29	JP-3-144634	06-20-1991	Konica Corp.		abs
	N30	JP-3-198049	08-29-1991	Fuji Photo Film Co. Ltd.		abs
	N31	JP-6-75172	09-21-1994	Fuji Photo Film Co. Ltd.		abs
	N32	JP-8-301841	11-19-1996	Green Cross Corp. et al.		abs
	N33	JP-10-306078	11-17-1998	Mitsubishi Chemical Corp.		abs
	O1	LB-6124	01-12-2000	Bayer Corporation.		
	T-F1	CL-38688	06-04-1993	Ciba-Geigy AG		
	T-I1	DE-487014	11-14-1929	I.G. Farbenindustrie Akt.-Ges.		
	T-I3	DE-523437	04-02-1931	I.G. Farbenindustrie Akt.-Ges.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P7	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway," <i>TIBS</i> 19, July 1994; pp. 279-283	
	P9a	Baka et al., "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis," <i>Expert Opinion Therapeutic Targets</i> , 2006, Vol. 10, No.6, pp. 867-876	
	P10	Balant et al., "Metabolic Considerations in Prodrug Design," Chapter Twenty-Three In: Burger's Medicinal Chemistry and Drug Discovery, 5 <sup>th</sup> ed. John Wiley & Sons, Inc., New York, 1995: Vol. 1,pp. 949-982	
	P17	Berge et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> . January 1977:1-19, Vol. 66, No. 1	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

26

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P22	Martin-Blanco, "p38 MAPK signalling cascades: ancient roles and new functions," <i>BioEssays</i> , 22:637-645, 2000	
	P23	Foussard-Blanpin, Odette, "Comparative pharmacological study of substituted carboxamides upon central nervous system," <i>Ann. Pharm. Fr.</i> (1982), 40 (4), pp. 339-350	
	P25	Boltag et al., "Raf pathway inhibitors in oncology," <i>Current Opinion in Investigational Drugs</i> (2003) 4(12); pp. 1436-1441.	
	P26	Bolton et al., "Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy," <i>Annual Reports In Medicinal Chemistry</i> , Vol. 29, 1994, pp. 165-174	
	P28a	Boyer, S.J., "Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships," <i>Current Topics in Medicinal Chemistry</i> , 2002, Vol. 2, pp. 973-1000	
	P50	Copéret et al., "A Simple And Efficient Method for the Preparation of Pyridine-N-oxides II," <i>Tetrahedron Letters</i> , Elsevier Science Ltd., Pergamon Press, Oxford, UK 1998; Vol. 39, pp. 761-764	
	P53a	Crump, Micheal, "Inhibition of raf kinase in the treatment of acute myeloid leukemia," <i>Medline Abstract ISSN:1361-6128, Current Pharmaceutical Design</i> , Vol. 8, Issue 25, 2002, pp. 2243-2248	
	P57	Daum et al., "The ins and outs of Raf kinases," <i>TIBS</i> 19, November 1994, pp. 474-480	
	P66	Dumas, J. "Protein kinase inhibitors from the urea class," <i>Curr. Opin. in Drug Discovery and Dev.</i> , 5(s):718-727, 2002	
	P67	Dumas et al., "Discovery of a New Class of p38 Kinase Inhibitors," <i>Biorganic &amp; Medicinal Chemistry Letters</i> Vol. 10, (2000), pp. 2047-2050	
	P68	Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors," <i>Biorganic &amp; Medicinal Chemistry Letters</i> , 2000, Vol. 10, pp. 2051-2054	
	P68a	Dumas, J., "Growth factor receptor kinase inhibitors: Recent progress and clinical impact," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2001, Vol. 4, No. 4, pp. 378-389	
	P68b	Dumas, J., "Protein kinase inhibitors: emerging pharmacophores 1997-2000," <i>Expert Opinion on Therapeutic Patents</i> (2001) Vol. 11, No. 3, pp. 405-429	
	P68c	Dumas et al., "Orally Active p38 Kinase Inhibitors from the Urea Class," <i>Poster, 222nd American Cancer Society National Meeting</i> 2001, Med 1 256, 1 page	
	P68d	Dumas, J., "Raf Kinase Inhibitors," <i>Expert Opinion on Therapeutic Patients</i> , Vol. 8, No. 12, pp. 1749-1750, 1998	
	P69	Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2004, Vol. 7, Number 5, pp. 600-616	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

27

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P22	Martin-Blanco, "p38 MAPK signalling cascades: ancient roles and new functions," <i>BioEssays</i> , 22:637-645, 2000	
	P70	Dumas et al., "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2002, Vol. 12, pp. 1559-1562	
	P107	Gura, "Systems for identifying new drugs are often faulty." <i>Science</i> , 1997, Vol. 278, (5340), pp. 1041-1042, MEDLINE with Full text	
	P147	Kubo et al., "Synthesis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors." <i>Proceedings of the American Association of Cancer Res.</i> , 2002, Vol. 43, p. 182, abstract no. 913	
	P149	Kumar et al., "Drugs targeted against protein kinases" <i>Expert Opin. Emerging Drugs</i> 6(2):303-315 (2001)	
	P166	Lyons et al., "Discovery of a novel Raf kinase inhibitor," <i>Endocrine-Related Cancer</i> , 2001, Vol. 8, pp. 219-225	
	P224	Regan et al., "Pyrazole Urea-Based Inhibitors of p38 MAP kinase: From Lead Compound to Clinical Candidate," <i>J. Med. Chem.</i> 45:2994-3008, 2002	
	P248	Smith et al., "Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2001, Vol. 11, pp. 2775-2778	
	P249	Smith et al., (Abstract) "Recent Advances in the Research and Development of RAF Kinase Inhibitors," <i>Current Topics in Medicinal Chemistry</i> 6(11):1071-1089 (2006)	
	P276	Thaimattam et al., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," <i>Bioorganic &amp; Medicinal Chemistry</i> , 2004, Vol. 12, pp. 6415-6425	
	P278	Thompson et al., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery," <i>Curr. Opin. Pharmacol.</i> , August 2005, Vol. 5, Number 4, pp. 350-356	
	P294	Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," <i>Chemistry &amp; Biology</i> , 1997, Vol. 4, Number 6, pp. 423-431.	
	P312	Kubo et al., "Synthesis and Structure-Activity Relationship of Quinazoline-Urea Derivatives as Novel Orally Active VEGF Receptor Tyrosine Kinase Selective Inhibitors," <i>Proceedings of the American Association of Cancer Res.</i> , 2002, Vol. 43, p. 182, abstract no. 913	
	P313	Riedl et al., # 4956 "Potent Raf Kinase Inhibitors from the Diphenylurea Class: Structure Activity Relationships," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 42, March 2001 (2001-03), page 923, 92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001	
	P315	Abstract of DE 3305866 A1, August 23, 1984, BASF AG et al.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

28

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P316	Abstract of EP 4931 A (Equivalent 4,240,820), Bayer AG, 1 page	
	P317	Abstract of EP 16371 (1980), 1 page, Hoffmann-La Roche AG	
	P318	Abstract of EP 16371, October 1, 1980, 1 page	
	P319	Abstract of EP 116932, August 29, 1984, 2 pages.	
	P320	Abstract of EP 116932, (1984), 2 pages, BASF AG	
	P321	Abstract of EP 0202538, (1986), 3 pages	
	P322	Abstract of EP 0202538 A1, "Growth Promoting Agents, November 26, 1986, 4 pages, Bayer AG	
	P323	Abstract of EP 0405233A1, Mitsubishi Kasei Corp., 2 pages	
	P324	Abstract of EP 0405233A1, Tetsuo Sekiya et al., 1 page	
	P325	Abstract of EP 0676395A2, (1995), 3 pages, Hoechst AG	
	P326	Abstract of EP 676395, (U.S. equivalent 5,698,581), December 16, 1997, 1 page	
	P327	Patent Abstracts of Japan 02-022650, 01-25-1990, 2 pages, Konica Corp.	
	P328	esp@cenet Abstracts of Japan 02-022650, 01-25-1990, 1 page	
	P329	Patent Abstracts of Japan 02-023337, 01-25-1990, 2 pages, Konica Corp.	
	P329a	Patent Abstracts of Japan 63-214752, 09-07-1988, 2 pages, family member of JP 6-07512 B4, Fuji Photo Film Co. Ltd.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

29

of

37

***Complete if Known***

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P330	esp@cenet Abstract of Japan 02-023337, 1 page	
	P331	Abstract of JP 55162772 A2, Preparation of Substituted Acetic Acid Derivatives, Shiongi & Co., Ltd. December 1980, 1 page	
	P332	Esp@cenet Abstract of WO 9822103, 28 May 1998, Philip Hedge et al.	
	P332a	Abstract of WO 9822098 A2, QLT Phototherapeutics Inc. et al., 05-28-1998, 1 page	
	P333a	Abstract of WO 9822103 A1, Zeneca Limited, published 05-28-1998, 1 page	
	P333b	Abstract of WO 9852559 A1, Bayer Corp. et al., published 11-26-1998, 1 page	
	P333c	Abstract of WO 9852562 A1, Verkaik, MSE, et al., published 11-26-1998, 1 page	
	P333d	Abstract of WO 9900357 A1, Vertex Pharm. Inc., published 01-07-1999, 1 page	
	P333e	Abstract of WO 9900364 A1, Pharmacia & Upjohn S.P.A. et al., published 01-07-1999, 1 page	
	P333f	Abstract of WO 9932096 A2, Janssen Pharm NV, published 07-01-1999, 1 page	
	P333g	Abstract of WO 9932106 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333h	Abstract of WO 9932148 A1, Beth Israel Deaconess Medical Center et al., pub. 07-01-1999, 1 page	
	P333i	Abstract of WO 9932436 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333j	Abstract of WO 9932455 A1, Bayer Corp., published 07-01-1999, 1 page	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

30

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P333k	Abstract of WO 9932457 A1, Hoechst Marion Roussel Deutschland GmbH et al., published 07-01-1999, 1 page	
	P334	Capius 72:79045, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas," Dr. A. Wander, October 15, 1969, 6 pages	
	P335	Capius 84:180049, Abstract JP 56029871, "Substituted acetic acid derivatives," Hamada, Yoshinori et al., July 10, 1981, 1 page	
	P336	Capius 84:43857, Abstract JP 58021626, "Aikanoic acid derivatives containing a pyridine ring," Maeda, Ryozo et al., May 2, 1983, 1 page	
	P337	Capius 86:72448, Abstract JP 57053785, "Pyridine derivatives," Maeda, Ryozo et al., November 15, 1982, 1 page	
	P339	Capius 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives," November 15, 1982, 1 page, Chugai Pharmaceutical Co., Ltd.	
	P340	Capius 113:106314, Abstract of JP 2022650, "Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove leuco cyan dye," Noboru Mizukura et al., January 25, 1990, 1 page	
	P341	Capius 113:142130, Abstract of JP 2023337, "Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler," Toshihiko Yagi et al., January 25, 1990, 1 page	
	P346	Capius 127:34137f, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation," Kazuo Kubo et al., May 15, 1997, WO 97/17329	
	P347	Capius 131:58658k, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas," Miller, Scott, et al. July 1, 1999, WO 99 32,436	
	P348	Capius 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38 kinase inhibitors," Jacques Dumas et al., July 1, 1999, WO 99/32110	
	P352	"Beilstein number" Collection, 28 pp. (1997)	
	P353	"Beilstein number" Collection, 4 pp. (1997)	
	P354	Derwent World Patents Index Search, pp. 20-26. (1997)	
	P355	Dumas, J. "CAS Substructure," May 6, 1997, pp. 1-29	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/788,426
				Filing Date	March 1, 2004
				First Named Inventor	Jacques Dumas
				Art Unit	1625
				Examiner Name	Heidi L. Reese
Sheet	31	of	37	Attorney Docket Number	BAYER-0044

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P356	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pp. 1-19	
	P357	Scott, Bill, "Substructure #2," November 25, 1997, pp. 1-3	
	P358	Scott, Bill, "Substructure Search," December 2, 1997, pp. 1-49	
	P359	Substructure Search, pp. 1-29. (1997)	
	P360	Wild, Hanno, "Substructure #1," search, pp. 1-150, 1996	
	P361	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749, filing date of 12/22/97, Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, 2 pages	
	P362	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399, filing date of 5/22/98, Patent 6187799 issued 2/13/2001, Inhibition of Raf Kinase Activity Using Aryl Ureas, 1 page	
	P363	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filing date of 10/22/99, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 3 pages	
	P364	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filing date of 10/22/99, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, 1 page	
	P365	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filing date of 12/10/1999, Inhibition Of p38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas, 1 page	
	P366	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Rat Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P367	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P368	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604, filing date of 2/2/01, Publication No. US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P369	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659, filing date of 2/2/01, Publication No.: US 2001-0011135 A1, Publication Date: August 2, 2001, Omega-carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P370	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672, filing date of 2/2/01, Publication No.: US 2001-0016659 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	

Examiner Signature	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

32

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYFR-0044

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P371	A "Notice of References Cited" from the USPTO for U.S. application 09/773,675, filing date of 2/2/01, Publication No.: US 2001-0011136-A1 , Publication Date: August 2, 2001, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P372	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935 filing date of 12/22/98, Inhibition Of p36 Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P373	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936, filing date of 12/22/98, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, 1 page	
	P374	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920, filing date of 2/7/01, inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas, 1 page	
	P375	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915, filing date of 9/10/01, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P376	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226, filing date of 01/11/2002, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P376a	Co-pending application Serial No. 09/458,014, filed December 10, 1999, Dumas et al.	
	P377	Abandoned application Serial No. 09/776,935 filed December 22, 1998, Dumas et al.	
	P378	Co-pending application Serial No. 09/776,936 filed December 22, 1998, Miller et al.	
	P379	Issued application Serial No. 09/889,227 filed July 12, 2000, Riedl et al., issued as 7351834, 4/1/2008	
	P380	Co-pending application Serial No. 09/993,647 filed November 27, 2001, Riedl et al., published as 2003-0161442, 9/25/2003	
	P381	Issued application Serial No. 10/060,396 filed February 1, 2002, Miller et al., patent 7517880, issued 4/14/2009, also published as 2004-0102636, 5/27/2004	
	P382	Issued application Serial No. 10/071,248 filed February 11, 2002, Riedl et al., patent 7528255, issued 5/5/2009, also published as 2003-139605, 7/24/2003	
	P383	Abandoned application Serial No. 10/086,417 filed March 4, 2002, Riedl et al., published as 2003-0105091, 6/5/2003	
	P384	Abandoned application Serial No. 10/125,369 filed April 19, 2002, Dumas et al., published as 2003-0207914, 11/6/2003	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

33

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P385	Abandoned application Serial No. 10/308,187 filed December 3, 2002, Carter et al., published as 2003-0232765, 12/16/2003	
	P386	Abandoned application Serial No. 10/361,844 filed February 11, 2003, Dumas et al., published as 2004-0023961, 2/5/2004	
	P387	Abandoned application Serial No. 10/361,850 filed February 11, 2003, Dumas et al., published as US 2003-0216396, 11/20/2003	
	P388	Co-pending application Serial No. 10/361,859 filed February 11, 2003, Dumas et al., published as 2003-0216446, 11/20/2003	
	P389	Co-Pending U.S. Patent Application No. 10/895,985 filed July 22, 2004, Boyer et al., published as US 2005-0038080, 2/17/2005	
	P389b	Co-Pending U.S. Patent Application No. 11/932,548 filed October 31, 2007, Dumas et al..	
	P390	Co-Pending U.S. Patent Application No. 12/084,662 filed May 7, 2008, Sandner et al., published as 2010-0035888, 2/11/2010.	
	P391	Co-Pending U.S. Patent Application No. 12/086,454 filed June 12, 2008, Weber et al.	
	P391a	Co-Pending U.S. Patent Application No. 12/093,515 filed November 13, 2008, Wilhelm et al.	
	P392	Co-Pending U.S. Patent Application No. 12/095,611 filed May 30, 2008, Smith et al.	
	P393	Co-Pending U.S. Patent Application No. 12/156,524 filed June 20, 2008, Smith et al.	
	P394	Co-Pending U.S. Patent Application No. 12/294,979 filed September 29, 2008, Wilhelm et al.	
	P394a	Co-Pending U.S. Patent Application No. 12/421,690 filed April 10, 2009, Dumas et al..	
	P395	Co-Pending U.S. Patent Application No. 12/444,974 filed April 9, 2009, Grunenberg et al.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

34

of

37

**Complete if Known**

<i>Application Number</i>	10/788,426
<i>Filing Date</i>	March 1, 2004
<i>First Named Inventor</i>	Jacques Dumas
<i>Art Unit</i>	1625
<i>Examiner Name</i>	Heidi L. Reese

Attorney Docket Number BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P396	Co-Pending U.S. Patent Application No. 12/514,129 filed May 8, 2009, Grunenberg et al.	
	P397	Co-Pending U.S. Patent Application No. 12/514,715 filed May 13, 2009, Stiehl et al.	
	P398	Co-Pending U.S. Patent Application No. 12/520,618 filed June 22, 2009, Smith et al.	
	P399	Co-Pending U.S. Patent Application No. 12/520,609 filed June 22, 2009, Smith et al.	
	P400	Co-pending U.S. Patent Application No. 12/523,652 filed July 17, 2009, Wilhelm et al.	
	P401	Co-pending U.S. Patent Application No. 12/523,697 filed July 17, 2009, Wilhelm et al.	
	P402	Co-Pending U.S. Patent Application No. 12/628,735 filed December 1, 2009, Dumas et al.	
	P402a	Co-Pending U.S. Patent Application No. 12/692,845 filed January 25, 2010, Dumas et al.	
	P403	Co-Pending Application PCT/US09/61506, filed October 21, 2009, Carol Pena	
	P404	International search report for International Application No. PCT/US98/10375 dated 9/3/98, Inhibition Of p38 Kinase Activity By Aryl Ureas, publication No. 98/52558, publication date 11/26/1998, 1 page	
	P405	International search report for International Application No. PCT/US98/10376 dated 7/30/98, Raf Kinase Inhibitors, publication No. WO 98/52559, publication date 11/26/1998, 1 page	
	P406	International search report for International Application No. PCT/US98/26078 dated 4/2/99, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication no. WO 99/32106, publication date 7/1/1999, 2 pages	
	P407	International search report for International Application No. PCT/US98/26079 dated 4/12/99, Inhibition Of p38 Kinase Activity Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32110, publication date 7/1/1999, 1 page	
	P408	International search report for International Application No. PCT/US98/26080 dated 4/12/99, Inhibition Of p38 Kinase Using Substituted Heterocyclic Ureas, publication No. WO 99/32111, publication date 7/1/1999, 1 page	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

35

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P409	International search report for International Application No. PCT/US98/26081 dated 4/2/99, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. WO 99/32436, publication date 7/1/1999, 1 page	
	P410	International search report for International Application No. PCT/US98/26082 dated 5/12/99, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32455, publication date 7/1/1999, 1 page	
	P411	International search report for International Application No. PCT/US98/27265, dated 3/2/99, Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas, publication No. WO 99/32463, publication date 7/1/99, 1 page	
	P412	International search report for International Application No. PCT/US00/00648 dated 6/29/00, Omega-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors, publication No. WO 00/42012 A1, publication date 7/20/2000, 2 pages	
	P413	International search report for International Application No. PCT/US00/00768 dated 5/16/00, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication No. WO 00/41698 A1, publication date 7/20/2000, 1 page	
	P414	International search report for International Application No. PCT/US02/12064 dated 9/20/02, HETEROCARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS, publication No. 02/085859, publication date 10/31/2002, 2 pages	
	P415	International search report for International Application No. PCT/US02/12066 dated 9/27/02, Inhibition Of Raf Kinase Quinolyl, Isoquinolyl Or Pyridyl Ureas, publication No. 02/085857, publication date 10/31/2002, 2 pages	
	P416	Supplemental search report from the EPO for European application EP 98963809.3 dated 3/30/01, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, publication No. 1049664, publication date 7/1/1999, granted 3/16/2005, 4 pages	
	P417	Supplemental search report from the EPO for European application EP 98963810.1 dated 12/21/00, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. 1056725, publication date 7/1/1999, granted 6/7/2006, 4 pages	
	P418	Supplemental search report from the EPO for European application EP 98965981.8 dated 12/21/00, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication No. 1047418, publication date 7/1/1999, granted 7/27/2005, 8 pages	
	P419	Supplemental search report from the EPO for European application EP 00903239.2 dated 8/7/02, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, publication no. EP 1140840, published 7/20/2000, granted 3/22/2006, 6 pages	
	P420	Supplemental search report from the EPO for European application EP 00905697.1 dated 2/7/08, Omega-Carboxyaryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication no. EP 1158985, 7/20/2000, 9 pages	
	P431	English abstract of JP 10-306078, 1998-11-17, Patent Abstracts of Japan, 2 pages	
	P432	English abstract of JP 08-301841, 1996-11-19, Patent Abstracts of Japan, 2 pages	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

36

of

37

**Complete if Known**

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese

Attorney Docket Number

BAYER-0044

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P433	English abstract of JP 03-198049, 1991-08-29, Patent Abstracts of Japan, 1 page	
	P434	English abstract of JP 03-144634, 1991-06-20, Patent Abstracts of Japan, 1 page	
	P435	English abstract of JP 03-053247, 1991-03-07, Patent Abstracts of Japan, 1 page	
	P436	English abstract of JP 02-150840, 1990-06-11, Patent Abstracts of Japan, 1 page	
	P437	English abstract of JP 02-108048, 1990-04-19, Patent Abstracts of Japan, 1 page	
	P438	English abstract of JP 02-105146, 1990-04-17, Patent Abstracts of Japan, 1 page	
	P439	English abstract of JP 02-035450, 1990-02-06, Patent Abstracts of Japan, 1 page	
	P440	English abstract of JP 01-200254, 1989-08-11, Patent Abstracts of Japan, 1 page	
	P441	English abstract of JP 01-259360, 1989-10-17, Patent Abstracts of Japan, 2 pages	
	P442	English abstract of JP 01-102461, 1989-04-20, Patent Abstracts of Japan, 1 page	
	P443	English abstract of JP 06-120039, 1994-04-28, Patent Abstracts of Japan, 1 page	
	P444	English abstract of JP 05-180862, 1993-07-23, Patent Abstracts of Japan, 1 page	
	P445	English abstract of JP 05-163170, 1993-06-29, Patent Abstracts of Japan, 1 page	
	P446	English abstract of JP 05-077375, 1993-03-30, Patent Abstracts of Japan, 1 page	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

37

of

37

**Complete if Known**

<i>Application Number</i>	10/788,426
<i>Filing Date</i>	March 1, 2004
<i>First Named Inventor</i>	Jacques Dumas
<i>Art Unit</i>	1625
<i>Examiner Name</i>	Heidi L. Reese

Attorney Docket Number

BAYER-0044

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P447	English abstract of JP 05-076072, 1993-03-26, Patent Abstracts of Japan, 2 pages	
	P448	English abstract of JP 50-149668 A and JP 56-29871 B, Derwent World Patents Index, Dialog File No. 351, Acc. No. 1488399, 3 pages	
	P449	English abstract of JP 53-086033, 1978-07-29, Patent Abstracts of Japan, 1 page	
	P450	English abstract of JP 54-032468, 1979-03-09, Patent Abstracts of Japan, 1 page	
	P451	English abstract of JP 55-098152, 1980-07-25, Patent Abstracts of Japan, 1 page	
	P452	English abstract of JP 64-009455, 1989-01-12, Patent Abstracts of Japan, 1 page	
	P453	English abstract of JP 02-023337, 1979-03-09, Patent Abstracts of Japan, 2 pages	
	P454	English abstract of EPA 0379915/EP-A1, 1990-08-01, 2 pages	
	P455	English abstract of DD 253997 A, 1988-02-10, 1 page	
	P456	English abstract of DE511468, European Patent Office, 2 pages; 10/30/1930	
	P457	Co-Pending U.S. Patent Application No. 12/619,913, filed November 17, 2009, Ranges et al.	
	T-P3a	Arzneimitteltherapie, "Sorafenib" October 6, 2006, Auflage 18498, 7 pages English translation	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.